Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

LAB - Standard BioTools Inc. So'nggi Yangiliklar | Finranks

Home

LAB

S

Standard BioTools Inc. (LAB)

NMS – Real vaqt narxi. Valyuta: USD

0.90

-0.06 (-6.34%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

0.90

+0.00 (0.01%)

Bozordan keyin: Mar 27, 2026, 7:14 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results

Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results

BOSTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter and fiscal year ended December 31, 2025.

Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

BOSTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S. market close.

Standard BioTools Completes Sale of SomaLogic to Illumina

Standard BioTools Completes Sale of SomaLogic to Illumina

Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter and full year 2025. Standard BioTools expects fourth quarter 2025 combined company revenue of approximately $56 million and revenue from continuing operations of approximately $24 million.

Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry

Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry

LOS ANGELES & SAN FRANCISCO--(BUSINESS WIRE)-- #Biotech--MI & Standard BioTools integrate HCR™ Gold with the Hyperion™ Imaging System to enable amplified RNA and protein detection for Imaging Mass Cytometry.

Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks

Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks

Following global commercial launch in September, Illumina Protein Prep's "out of the box" solution drives extraordinary accessibility to proteomics for researchers, with over 40,000 samples processed Sydney Mass Spectrometry is the first facility in the wider Asia Pacific region to offer Illumina Protein Prep, adding to a growing list of institutions revealing biological insights with exceptional clarity at scale Recent collaborations and projects including Genomics England and PRECISE-SG100K highlight advancements in proteomic profiling across diverse populations and research areas SAN DIEGO , Nov. 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that Illumina Protein Prep is delivering the broadest coverage of the blood proteome on the market at the lowest cost per protein target for more than 40 customers across 16 sites globally. Labs of all sizes are creating powerful layers of omic data for a range of diseases that enrich datasets generated by biobank programs around the world.

Standard BioTools Reports Third Quarter 2025 Financial Results

Standard BioTools Reports Third Quarter 2025 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended September 30, 2025.

Videolar

No Data

There is no data to display

Press-relizlar

Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results

Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results

BOSTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter and fiscal year ended December 31, 2025.

Standard BioTools Completes Sale of SomaLogic to Illumina

Standard BioTools Completes Sale of SomaLogic to Illumina

Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter and full year 2025. Standard BioTools expects fourth quarter 2025 combined company revenue of approximately $56 million and revenue from continuing operations of approximately $24 million.

Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry

Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry

LOS ANGELES & SAN FRANCISCO--(BUSINESS WIRE)-- #Biotech--MI & Standard BioTools integrate HCR™ Gold with the Hyperion™ Imaging System to enable amplified RNA and protein detection for Imaging Mass Cytometry.